Eric Karas insider trades: ARS Pharmaceuticals (SPRY) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Eric reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | SPRY | ↓ Sell | 25,000 | $10.00 | $250K | Direct | Jun 12, 2026 (0d) |
| Jul 1, 2025 | SPRY | ↓ Sell | 15,000 | $16.99 | $255K | Direct | Jul 3, 2025 (2d) |
| Jun 18, 2025 | SPRY | ↓ Sell | 15,000 | $16.00 | $240K | Direct | Jun 20, 2025 (2d) |
| Mar 20, 2025 | SPRY | ↓ Sell | 10,000 | $14.00 | $140K | Direct | Mar 21, 2025 (1d) |
| Dec 4, 2024 | SPRY | ↓ Sell | 10,000 | $14.04 | $140K | Direct | Dec 4, 2024 (0d) |
| Sep 18, 2024 | SPRY | ↓ Sell | 10,000 | $14.00 | $140K | Direct | Sep 19, 2024 (1d) |
| Aug 19, 2024 | SPRY | ↓ Sell | 10,000 | $14.00 | $140K | Direct | Aug 21, 2024 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SPRY insiders
Open-market trades in the last 12 months
About Eric Karas's insider trades
Eric Karas is Chief Commercial Officer at ARS Pharmaceuticals (SPRY). Since Aug 19, 2024, Eric has reported no open-market purchases and 7 sales worth $1.3M on SEC Form 4. In the last 12 months: 1 sale ($250K).
Their filings also include option exercises (7 filings), grants and awards (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SPRY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.